KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Acquisitions & Divestments: 2010-2012

Historic Change in Acquisitions & Divestments for Emergent BioSolutions (EBS) over the last 2 years, with Mar 2012 value amounting to $2.0 million.

  • Emergent BioSolutions' Change in Acquisitions & Divestments was N/A to $2.0 million in Q1 2012 from the same period last year, while for Mar 2012 it was $6.2 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2012, which is 53.74% down from last year.
  • As of Q1 2012, Emergent BioSolutions' Change in Acquisitions & Divestments stood at $2.0 million, which was up 293.20% from $500,000 recorded in Q4 2011.
  • In the past 5 years, Emergent BioSolutions' Change in Acquisitions & Divestments ranged from a high of $10.0 million in Q2 2010 and a low of $500,000 during Q4 2011.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $2.2 million (2011), whereas its average is $5.2 million.
  • Data for Emergent BioSolutions' Change in Acquisitions & Divestments shows a maximum YoY tumbled of 95.00% (in 2011) over the last 5 years.
  • Emergent BioSolutions' Change in Acquisitions & Divestments (Quarterly) stood at $10.0 million in 2010, then slumped by 95.00% to $500,000 in 2011, then reached $2.0 million in 2012.
  • Its last three reported values are $2.0 million in Q1 2012, $500,000 for Q4 2011, and $1.5 million during Q3 2011.